Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study.

Abstract

The combination of gemcitabine and cisplatin induced a high response rate in both stage IIIB and IV NSCLC, with modest side effects. The regimen deserves further careful evaluation in a phase III prospective randomized trial.